Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children

M. Kato, S. Ishimaru, M. Seki, K. Yoshida, Y. Shiraishi, K. Chiba, N. Kakiuchi, Y. Sato, H. Ueno, H. Tanaka, T. Inukai, D. Tomizawa, D. Hasegawa, T. Osumi, Y. Arakawa, T. Aoki, M. Okuya, K. Kaizu, Koji Kato, Y. TaneyamaH. Goto, T. Taki, M. Takagi, M. Sanada, K. Koh, J. Takita, S. Miyano, S. Ogawa, A. Ohara, M. Tsuchida, A. Manabe

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

In the treatment of childhood acute lymphoblastic leukemia (ALL), excess shortening of maintenance therapy resulted in high relapse rate, as shown by our previous trial, TCCSG L92-13, in which maintenance therapy was terminated at 1 year from initiation of treatment. In this study, we aimed to confirm the long-term outcome of L92-13, and to identify who can or cannot be cured by shorter duration of maintenance therapy. To obtain sentinel cytogenetics information that had been missed before, we performed genetic analysis with genomic microarray and target intron-capture sequencing from diagnostic bone marrow smear. Disease-free survival (DFS) at 10 years from the end of therapy was 66.0±2.8%. Females (n=138) had better DFS (74.6±3.7%) than males (n=142, 57.5±4.2%, P=0.002). Patients with TCF3-PBX1 (n=11) and ETV6-RUNX1 (n=16) had excellent DFS (90.9±8.7% and 93.8±6.1%, respectively), whereas high hyperdiploidy (n=23) was the most unfavorable subgroup, with 56.6±10.3% of DFS. Short duration of therapy can cure more than half of pediatric ALL, especially females, TCF3-PBX1 and ETV6-RUNX1. Our retrospective observations suggest a gender/karyotype inhomogeneity on the impact of brief therapy.

Original languageEnglish
Pages (from-to)580-584
Number of pages5
JournalLeukemia
Volume31
Issue number3
DOIs
Publication statusPublished - Mar 1 2017
Externally publishedYes

Fingerprint

Maintenance Chemotherapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Therapeutics
Polyploidy
Karyotype
Cytogenetics
Introns
Bone Marrow
Pediatrics
Recurrence

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kato, M., Ishimaru, S., Seki, M., Yoshida, K., Shiraishi, Y., Chiba, K., ... Manabe, A. (2017). Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children. Leukemia, 31(3), 580-584. https://doi.org/10.1038/leu.2016.274

Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children. / Kato, M.; Ishimaru, S.; Seki, M.; Yoshida, K.; Shiraishi, Y.; Chiba, K.; Kakiuchi, N.; Sato, Y.; Ueno, H.; Tanaka, H.; Inukai, T.; Tomizawa, D.; Hasegawa, D.; Osumi, T.; Arakawa, Y.; Aoki, T.; Okuya, M.; Kaizu, K.; Kato, Koji; Taneyama, Y.; Goto, H.; Taki, T.; Takagi, M.; Sanada, M.; Koh, K.; Takita, J.; Miyano, S.; Ogawa, S.; Ohara, A.; Tsuchida, M.; Manabe, A.

In: Leukemia, Vol. 31, No. 3, 01.03.2017, p. 580-584.

Research output: Contribution to journalArticle

Kato, M, Ishimaru, S, Seki, M, Yoshida, K, Shiraishi, Y, Chiba, K, Kakiuchi, N, Sato, Y, Ueno, H, Tanaka, H, Inukai, T, Tomizawa, D, Hasegawa, D, Osumi, T, Arakawa, Y, Aoki, T, Okuya, M, Kaizu, K, Kato, K, Taneyama, Y, Goto, H, Taki, T, Takagi, M, Sanada, M, Koh, K, Takita, J, Miyano, S, Ogawa, S, Ohara, A, Tsuchida, M & Manabe, A 2017, 'Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children', Leukemia, vol. 31, no. 3, pp. 580-584. https://doi.org/10.1038/leu.2016.274
Kato M, Ishimaru S, Seki M, Yoshida K, Shiraishi Y, Chiba K et al. Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children. Leukemia. 2017 Mar 1;31(3):580-584. https://doi.org/10.1038/leu.2016.274
Kato, M. ; Ishimaru, S. ; Seki, M. ; Yoshida, K. ; Shiraishi, Y. ; Chiba, K. ; Kakiuchi, N. ; Sato, Y. ; Ueno, H. ; Tanaka, H. ; Inukai, T. ; Tomizawa, D. ; Hasegawa, D. ; Osumi, T. ; Arakawa, Y. ; Aoki, T. ; Okuya, M. ; Kaizu, K. ; Kato, Koji ; Taneyama, Y. ; Goto, H. ; Taki, T. ; Takagi, M. ; Sanada, M. ; Koh, K. ; Takita, J. ; Miyano, S. ; Ogawa, S. ; Ohara, A. ; Tsuchida, M. ; Manabe, A. / Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children. In: Leukemia. 2017 ; Vol. 31, No. 3. pp. 580-584.
@article{a78647d14d7d4b13b2cc7a5be29ee69c,
title = "Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children",
abstract = "In the treatment of childhood acute lymphoblastic leukemia (ALL), excess shortening of maintenance therapy resulted in high relapse rate, as shown by our previous trial, TCCSG L92-13, in which maintenance therapy was terminated at 1 year from initiation of treatment. In this study, we aimed to confirm the long-term outcome of L92-13, and to identify who can or cannot be cured by shorter duration of maintenance therapy. To obtain sentinel cytogenetics information that had been missed before, we performed genetic analysis with genomic microarray and target intron-capture sequencing from diagnostic bone marrow smear. Disease-free survival (DFS) at 10 years from the end of therapy was 66.0±2.8{\%}. Females (n=138) had better DFS (74.6±3.7{\%}) than males (n=142, 57.5±4.2{\%}, P=0.002). Patients with TCF3-PBX1 (n=11) and ETV6-RUNX1 (n=16) had excellent DFS (90.9±8.7{\%} and 93.8±6.1{\%}, respectively), whereas high hyperdiploidy (n=23) was the most unfavorable subgroup, with 56.6±10.3{\%} of DFS. Short duration of therapy can cure more than half of pediatric ALL, especially females, TCF3-PBX1 and ETV6-RUNX1. Our retrospective observations suggest a gender/karyotype inhomogeneity on the impact of brief therapy.",
author = "M. Kato and S. Ishimaru and M. Seki and K. Yoshida and Y. Shiraishi and K. Chiba and N. Kakiuchi and Y. Sato and H. Ueno and H. Tanaka and T. Inukai and D. Tomizawa and D. Hasegawa and T. Osumi and Y. Arakawa and T. Aoki and M. Okuya and K. Kaizu and Koji Kato and Y. Taneyama and H. Goto and T. Taki and M. Takagi and M. Sanada and K. Koh and J. Takita and S. Miyano and S. Ogawa and A. Ohara and M. Tsuchida and A. Manabe",
year = "2017",
month = "3",
day = "1",
doi = "10.1038/leu.2016.274",
language = "English",
volume = "31",
pages = "580--584",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children

AU - Kato, M.

AU - Ishimaru, S.

AU - Seki, M.

AU - Yoshida, K.

AU - Shiraishi, Y.

AU - Chiba, K.

AU - Kakiuchi, N.

AU - Sato, Y.

AU - Ueno, H.

AU - Tanaka, H.

AU - Inukai, T.

AU - Tomizawa, D.

AU - Hasegawa, D.

AU - Osumi, T.

AU - Arakawa, Y.

AU - Aoki, T.

AU - Okuya, M.

AU - Kaizu, K.

AU - Kato, Koji

AU - Taneyama, Y.

AU - Goto, H.

AU - Taki, T.

AU - Takagi, M.

AU - Sanada, M.

AU - Koh, K.

AU - Takita, J.

AU - Miyano, S.

AU - Ogawa, S.

AU - Ohara, A.

AU - Tsuchida, M.

AU - Manabe, A.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - In the treatment of childhood acute lymphoblastic leukemia (ALL), excess shortening of maintenance therapy resulted in high relapse rate, as shown by our previous trial, TCCSG L92-13, in which maintenance therapy was terminated at 1 year from initiation of treatment. In this study, we aimed to confirm the long-term outcome of L92-13, and to identify who can or cannot be cured by shorter duration of maintenance therapy. To obtain sentinel cytogenetics information that had been missed before, we performed genetic analysis with genomic microarray and target intron-capture sequencing from diagnostic bone marrow smear. Disease-free survival (DFS) at 10 years from the end of therapy was 66.0±2.8%. Females (n=138) had better DFS (74.6±3.7%) than males (n=142, 57.5±4.2%, P=0.002). Patients with TCF3-PBX1 (n=11) and ETV6-RUNX1 (n=16) had excellent DFS (90.9±8.7% and 93.8±6.1%, respectively), whereas high hyperdiploidy (n=23) was the most unfavorable subgroup, with 56.6±10.3% of DFS. Short duration of therapy can cure more than half of pediatric ALL, especially females, TCF3-PBX1 and ETV6-RUNX1. Our retrospective observations suggest a gender/karyotype inhomogeneity on the impact of brief therapy.

AB - In the treatment of childhood acute lymphoblastic leukemia (ALL), excess shortening of maintenance therapy resulted in high relapse rate, as shown by our previous trial, TCCSG L92-13, in which maintenance therapy was terminated at 1 year from initiation of treatment. In this study, we aimed to confirm the long-term outcome of L92-13, and to identify who can or cannot be cured by shorter duration of maintenance therapy. To obtain sentinel cytogenetics information that had been missed before, we performed genetic analysis with genomic microarray and target intron-capture sequencing from diagnostic bone marrow smear. Disease-free survival (DFS) at 10 years from the end of therapy was 66.0±2.8%. Females (n=138) had better DFS (74.6±3.7%) than males (n=142, 57.5±4.2%, P=0.002). Patients with TCF3-PBX1 (n=11) and ETV6-RUNX1 (n=16) had excellent DFS (90.9±8.7% and 93.8±6.1%, respectively), whereas high hyperdiploidy (n=23) was the most unfavorable subgroup, with 56.6±10.3% of DFS. Short duration of therapy can cure more than half of pediatric ALL, especially females, TCF3-PBX1 and ETV6-RUNX1. Our retrospective observations suggest a gender/karyotype inhomogeneity on the impact of brief therapy.

UR - http://www.scopus.com/inward/record.url?scp=84992380016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992380016&partnerID=8YFLogxK

U2 - 10.1038/leu.2016.274

DO - 10.1038/leu.2016.274

M3 - Article

C2 - 27698447

AN - SCOPUS:84992380016

VL - 31

SP - 580

EP - 584

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -